Stay updated with breaking news from Orum Therapeutic. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
SystImmune and Bristol Myers Squibb & Co (NYSE:BMY) announced an exclusive license and collaboration agreement for Sy...
SystImmune and Bristol Myers Squibb & Co (NYSE: BMY)
The ADC-focused deal between Bristol Myers Squibb and SystImmune could amount to $8.4 billion in total potential consideration.
The drug Bristol Myers Squibb pick up, ORM-6151, is an experimental type of antibody drug-conjugate for acute myeloid leukemia and high-risk myelodysplastic syndromes.
Bristol Myers Squibb has acquired Orum Therapeutics' experimental therapy to treat a type of blood cancer for a total value of up to $180 million, the privately held company said on Monday. The therapy, ORM-6151, which helps degrade a specific protein hard to treat previously, has received the U.S. Food and Drug Administration's (FDA) clearance for an early stage study. The deal includes an upfront payment of $100 million and milestone payments, Orum said, without disclosing further details.